Concepedia

Author

Julia Piasecki

Bristol-Myers Squibb (United States)

Also Known As

J Piasecki, J. Piasecki, Julia C. Piasecki, Julia Catherine Piasecki, Julia Piasecki

69

Publications

1.2K

Citations

9

H-Index

25

Concepts

All Affiliations

Bristol-Myers Squibb (United States)Memorial Sloan Kettering Cancer CenterUniversity of Alabama at BirminghamEmory UniversitySarah Cannon
JP

About

Julia Piasecki is an author at Bristol-Myers Squibb (United States) specializing in medicine, oncology, and immunology.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

3

3

205

2

Immunology

2

2

166

3

Allergy

1

1

12

4

Cell Biology

1

1

39

5

Clinical Immunology

1

1

12

Julia Piasecki

×

9

Publications

1.1K

Citations

9

H-Index

YearCitations

Ide-cel or Standard Regimens in Relapsed and Refractory Multiple Myeloma

Paula Rodríguez‐Otero, Sikander Ailawadhi, Bertrand Arnulf,

New England Journal of Medicine

2023

627

Apo2L/TRAIL and the Death Receptor 5 Agonist Antibody AMG 655 Cooperate to Promote Receptor Clustering and Antitumor Activity

Jonathan D. Graves, Jennifer J. Kordich, Tzu-Hsuan Huang,

Cancer Cell

2014

154

JCARH125, Anti-BCMA CAR T-cell Therapy for Relapsed/Refractory Multiple Myeloma: Initial Proof of Concept Results from a Phase 1/2 Multicenter Study (EVOLVE)

Sham Mailankody, Myo Htut, Kelvin P. Lee,

Blood

2018

124

Local Delivery of OncoVEXmGM-CSF Generates Systemic Antitumor Immune Responses Enhanced by Cytotoxic T-Lymphocyte–Associated Protein Blockade

Achim K. Moesta, Keegan S. Cooke, Julia Piasecki,

Clinical Cancer Research

2017

104

Ide-cel vs standard regimens in triple-class–exposed relapsed and refractory multiple myeloma: updated KarMMa-3 analyses

Sikander Ailawadhi, Bertrand Arnulf, Krina K. Patel,

Blood

2024

47

Combined therapy with the RANKL inhibitor RANK-Fc and rhApo2L/TRAIL/dulanermin reduces bone lesions and skeletal tumor burden in a model of breast cancer skeletal metastasis

Pamela M. Holland, Robert E. Miller, Jon C. Jones,

Cancer Biology & Therapy

2010

39

Orvacabtagene Autoleucel (orva-cel; JCARH125): A Fully Human BCMA-Targeted Second-Generation CAR T Cell Product Characterized By a Predominant Central Memory Phenotype with High in Vitro and In Vivo Proliferative Potential and Sustained In Vivo Persistence

Lucrezia Colonna, Garnet Navarro, Todd DeVries,

Blood

2020

15

Idecabtagene Vicleucel (ide-cel) Versus Standard (std) Regimens in Patients (pts) with Triple-Class-Exposed (TCE) Relapsed and Refractory Multiple Myeloma (RRMM): Updated Analysis from KarMMa-3

Paula Rodríguez‐Otero, Sikander Ailawadhi, Bertrand Arnulf,

Blood

2023

15

Anakinra (AKR) prophylaxis (ppx) in patients (pts) with relapsed/refractory multiple myeloma (RRMM) receiving orvacabtagene autoleucel (orva-cel).

Luciano J. Costa, Sham Mailankody, Paul Shaughnessy,

Journal of Clinical Oncology

2021

12

Page 1